Eli Lilly 2004 Annual Report Download - page 9

Download and view the complete annual report

Please find page 9 of the 2004 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 100

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100

PIPELINE
7
Major Marketed Products, continued
1987 Humatrope® for growth failure caused by pediatric growth hormone defi ciency
for replacement therapy for adult growth hormone defi ciency (1995)
for short stature caused by Turner syndrome (1997)
for idiopathic short stature (2003)
1983 Humulin® for type 1 and type 2 diabetes
New Drug Applications Under Review by the U.S. Food and Drug Administration
Exenatide for type 2 diabetes
(codeveloping with Amylin Pharmaceuticals, Inc.)
Drug Candidates in Late-Stage Investigation
Arxxant™ (ruboxistaurin) for diabetic microvascular complications
Prasugrel for acute coronary syndrome
(codeveloping with Sankyo Company, Ltd.)
Arzoxifene for prevention and treatment of osteoporosis, and for reducing the risk
of breast cancer
Selected Drug Candidates in Mid-Stage Investigation
Enzastaurin for glioblastoma, a type of brain tumor; non-Hodgkin’s lymphoma; and
other cancers
Inhaled insulin for non-injectable delivery of insulin
(codeveloping with Alkermes, Inc.)
Factor Xa inhibitor for prevention of deep vein thrombosis
Pruvanserin (5-HT2A antagonist)
for insomnia
Naveglitazar for type 2 diabetes
Gamma-secretase inhibitor for slowing the progression of Alzheimer’s disease
PPAR alpha agonist for reducing the progression of atherosclerosis
Note: All of this information is current as of February 14, 2005. The search for new drugs is risky and uncertain, and there are no guar-
antees. Remaining scientifi c and regulatory hurdles may cause pipeline compounds to be delayed or even to fail to reach the market.